RxDoctor Payments Data

Kimberly Hashin, MD

Internal Medicine · Pottsville, PANPI 1972576403

Payments from drug & device makers

$2,423in general payments, 2019–2025

Across 215 payments — averaging $11.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$224
  • AstraZeneca$169
  • Pfizer$149
  • Lilly USA, LLC$119
  • Amarin Pharma, Inc.$94
  • plus $445 from 13 others

What the payments were for

  • Food & beverage$2,423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,423 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$276,256
Medicare patients
457
Services billed
5,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban606$189,803
JardianceEmpagliflozin88$93,220
OzempicSemaglutide40$67,058
TrulicityDulaglutide166$60,722
XareltoRivaroxaban86$39,318
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$31,604
JanuviaSitagliptin Phosphate69$28,974
TradjentaLinagliptin19$18,729
RexultiBrexpiprazole45$16,477
JanumetSitagliptin Phos/Metformin Hcl11$16,230
XifaxanRifaximin18$13,846
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,914
Metoprolol Succinate1,084$10,671
Atorvastatin Calcium1,373$10,631
EntrestoSacubitril/Valsartan49$10,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$189,803606 claims
Boehringer IngelheimJardiance, Tradjenta$224$111,949107 claims
Novo NordiskOzempic$1,224$67,05840 claims
Lilly USA, LLCTrulicity$119$60,722166 claims
MerckJanuvia, Janumet$13$45,20480 claims
Johnson & JohnsonXarelto$30$39,31886 claims
GSKTrelegy Ellipta, Arexvy$47$19,86641 claims
NovartisEntresto$66$10,46149 claims
AbbVieSynthroid$79$3,935106 claims
AstraZenecaSymbicort$169$3,01814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pottsville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →